Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | RBP4 | P02753 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818669 | 0.88 | EPHX2 (0.57) | EPHX2HSD11B1TRPV1GAADPP4 | |
| SCHEMBL3818667 | 0.88 | EPHX2 (0.57) | EPHX2HSD11B1TRPV1GAADPP4 | |
| SCHEMBL4320157 | 0.88 | EPHX2 (0.56) | EPHX2HSD11B1TRPV1GAADPP4 | |
| SCHEMBL1349136 | 0.84 | EPHX2 (0.64) | EPHX2HSD11B1TRPV1GAADPP4 | |
| SCHEMBL14973800 | 0.84 | EPHX2 (0.59) | EPHX2HSD11B1TRPV1GAAMAPT | |
| SCHEMBL25154349 | 0.81 | EPHX2 (0.56) | EPHX2HSD11B1TRPV1GAARBP4 | |
| SCHEMBL25154314 | 0.81 | EPHX2 (0.56) | EPHX2HSD11B1TRPV1GAARBP4 | |
| SCHEMBL22668886 | 0.78 | EPHX2 (0.73) | EPHX2HSD11B1GAAMAPTTSHR | |
| SCHEMBL30582915 | 0.77 | EPHX2 (0.68) | EPHX2HSD11B1TRPV1GAAMAPT | |
| SCHEMBL22669112 | 0.77 | EPHX2 (0.71) | EPHX2HSD11B1TRPV1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2006-12-07 | — | — | US | claimed |
| EP-1601665-A2 | UREA DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078744-A2 | UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | claimed |
| US-7514562-B2 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | GLAXO GROUP LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1601665-A2 | UREA DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078744-A2 | UREA DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276447-A1 | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain | TRPV1, UTS2R, OPRL1 | EPHX2 3279/4885HSD11B1 3894/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.